Access cutting-edge urothelial cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access urothelial cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related urothelial cancer treatment provided free
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Sponsor: Gilead Sciences
Check if you qualify for this urothelial cancer clinical trial in New Haven, CT
If you're searching for urothelial cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced urothelial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.